Novavax Inc (NVAX)

[Golden Cross]

$NVAX Received its Third Buy in a Row
June 08 2022 - 07:05AM

After Cantor Fitzgerald and H.C. Wainwright gave Novavax (NASDAQ: NVAX) a Buy rating last month, the company received another Buy, this time from B.Riley Financial. Analyst Mayank Mamtani reiterated a Buy rating on Novavax today and set a price target of $181.00. The company's shares closed last Monday at $47.54, close to its 52-week low of $41.10. According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -32.2% and a 21.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
https://www.tipranks.com/news/blurbs/novavax-nvax-received-its-third-buy-in-a-row-2?utm_source=advfn.com&utm_medium=referral